メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
第1・薬剤部
病院局
藤田医科大学病院
概要
フィンガープリント
ネットワーク
プロファイル
(1)
研究成果
(21)
フィンガープリント
第1・薬剤部が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
100%
Colorectal Cancer
94%
Adverse Event
88%
Polypharmacy
87%
Rituximab
75%
Combination Therapy
63%
Dexamethasone
54%
Retrospective Study
52%
Prescription Drug
52%
Ramucirumab
50%
Ifosfamide
47%
Non Small Cell Lung Cancer
47%
Diffuse Large B Cell Lymphoma
47%
Erlotinib
47%
Carboplatin
47%
Meglumine
47%
Aprepitant
47%
Cancer Chemotherapy
47%
Fosaprepitant
47%
Cytomegalovirus
47%
Immune Checkpoint Inhibitor
47%
Liver Dysfunction
47%
Bevacizumab
47%
Nonhodgkin Lymphoma
47%
Bendamustine
47%
Vertebral Canal Stenosis
47%
Etoposide
47%
Adverse Drug Reaction
47%
Infection
47%
Blood Toxicity
47%
Allergic Reaction
47%
Bilirubin
47%
CD20 Antibody
47%
Benzodiazepine
47%
Musculoskeletal Disease
47%
Proteinuria
47%
Cytomegalovirus Infection
28%
Monotherapy
26%
Malignant Neoplasm
25%
Obinutuzumab
23%
Disease
23%
First-Line Chemotherapy
21%
Phlebitis
20%
Chemotherapy
18%
Anticarcinogen
17%
Epileptic Absence
16%
Prevalence
16%
Comorbidity
16%
Ribosome Protein
15%
Cancer of Unknown Primary Site
15%
Hypnotic
15%
Hyperlipidemia
13%
Thymoma
13%
Skin Disease
13%
Fluorouracil
13%
Pharmacotherapy
11%
Irinotecan
9%
Folinic Acid
9%
Metastatic Colorectal Cancer
9%
Vasculotropin
9%
Overall Survival
9%
Backache
9%
Colon Cancer
7%
Nivolumab
6%
Arterial Thromboembolism
6%
Venous Thromboembolism
6%
Medical History
6%
Musculoskeletal Pain
6%
Neurokinin 1 Receptor Antagonist
6%
Vincristine
5%
Cyclophosphamide
5%
Symptom
5%
Prednisolone
5%
Doxorubicin
5%
Keyphrases
Fosaprepitant
47%
Aprepitant
47%
Pharmaceutical Consultation
47%
Immune Checkpoint Inhibitors
47%
Cancer-associated Thrombosis
47%
L-OHP
47%
Drug Survey
47%
Hematopoietic Function
47%
Serum IgG Level
47%
Relapsed Lymphoma
47%
CBDCA
47%
R-CHOP Therapy
47%
Combination of Therapies
47%
System Restoration
47%
Early Palliative Care
47%
MFOLFOX6
33%
Palliative Care Interventions
27%
Calvert Formula
27%
TCR-T Therapy
23%
Thrombocytopaenia
20%
Visual Infusion Phlebitis Score
20%
Vascular Pain
20%
Delayed Vomiting
15%
Cancer of Unknown Primary
15%
Method Parameters
15%
Lymphocyte Count
15%
Ribosomal Protein Genes
15%
R-CHOP-14
15%
Absolute Reticulocyte Count
15%
R-CHOP-21
15%
CD20+
15%
Pleural Thymoma
13%
Self-management
11%
Anti-cancer Drug Treatment
11%
Bendamustine-rituximab
11%
National Comprehensive Cancer Network International Prognostic Index
9%
Infection Symptoms
9%
Population Groups
9%
Latent Factor Analysis
9%
High-dose Chemotherapy
7%
Acute Nausea
7%
Complete Control
7%
Questionnaire Form
7%
Hemoglobin Count
7%
Chemotherapy Dose
7%
Blood Transfusion Therapy
7%
Hemoglobin Synthesis
7%
Therapy Initiation
7%
Nivolumab
7%
Arterial Thromboembolism
7%
High Safety
6%
Platinum-based Agents
6%
Unresectable Rectal Cancer
6%
Unresectable Colon Cancer
6%
Injection Timing
6%
Reaction Rate
6%
Palliative Care Consultation
6%
Non-musculoskeletal
6%
Knee Arthroplasty
6%
Hematological Cancer
6%
Total Pain
6%
Body Surface Area
6%
Response Criteria
6%
International Working Groups
6%
Realist Evaluation
6%
Inpatient Palliative Care
6%
Transfer of Care
6%
Preferred Terms
5%
Duration of Infection
5%
Grade 23
5%
Medicine and Dentistry
Prescription Drug
52%
Spinal Stenosis
47%
Overall Survival
47%
Surgery
47%
Retrospective Study
47%
Symptomatic Treatment
47%
Pemetrexed
47%
Elderly Patient
47%
Immune Checkpoint Inhibitor
47%
Polypharmacy
47%
Blood Toxicity
47%
Spine Surgery
18%
Cancer of Unknown Primary Origin
15%
Analgesia
9%
Pain Measurement
9%
Backache
9%
Prevalence
9%
Orthopedics
9%
Venous Thromboembolism
7%
Nivolumab
7%
Arterial Thromboembolism
7%
Treatment of Non-Small Cell Lung Cancer
6%
Knee Arthroplasty
6%
Potentially Inappropriate Medication
5%